In A Competitive New Cancer Field, Infinity Looks For A Place To Play
This article was originally published in The Pink Sheet Daily
Executive Summary
Infinity presented positive efficacy data on its oral PI3 kinase inhibitor IPI-145 in CLL and lymphoma at ASCO, but other drug makers also released strong data on potential competitors that are further ahead in clinical development, sparking a stock sell off.